Literature DB >> 31211689

Severe, persistent neonatal hypoglycemia as a presenting feature in patients with congenital hypopituitarism: a review of our case series.

Shilpa Mehta1, Preneet Cheema Brar1.   

Abstract

Background Persistent hypoglycemia (PH) beyond 3 days of life warrants investigation which includes a critical sample. We report our case series of five neonates who presented with PH as the first sign of congenital hypopituitarism. Design This is a case series. Methods/Results This is a case series of five neonates evaluated at our academic institution in a 3-year period (2013-2016), who presented with persistent severe hypoglycemia and were subsequently diagnosed with congenital hypopituitarism. All neonates were full term (mean gestational age 39.8 ± 1.4 weeks) born by caesarian section with a mean weight of 3.5 ± 0.16 kg and a mean length of 51.2 ± 1.2 cm at birth. All five neonates had PH beyond 3 days with an average blood glucose (BG) <35 mg/dL at presentation, requiring a mean glucose infusion rate (GIR) of 7.22 ± 1.98 mg/kg/min. The average BG during the critical sample was 42 ± 0.16 mg/dL (three patients). The mean duration of requirement of the glucose infusion was 6.2 ± 3 days during the immediate neonatal period. Diagnosis of the hypopituitarism took 2-52 days from the initial presentation of hypoglycemia. Besides growth hormone (GH) deficiency, cortisol deficiency was diagnosed in all the five neonates. Neuroimaging findings in all the neonates were consistent with pituitary stalk interruption syndrome (hypoplastic anterior pituitary, ectopic posterior pituitary [EPP] and interrupted pituitary stalk). Conclusions Hypoglycemia is a common metabolic complication affecting an infant in the immediate neonatal period. Delay in the diagnosis of hypopituitarism presenting as hypoglycemia is the result of the lack of awareness among neonatologists and/or pediatricians. We propose that providers be cognizant that PH can be the only presentation of hypopituitarism in the neonatal period. Therefore, having a high index of suspicion about this condition can avoid a delay in the evaluation, diagnosis and treatment of hypopituitarism.

Entities:  

Keywords:  congenital hypopituitarism; hypoglycemia

Year:  2019        PMID: 31211689     DOI: 10.1515/jpem-2019-0075

Source DB:  PubMed          Journal:  J Pediatr Endocrinol Metab        ISSN: 0334-018X            Impact factor:   1.634


  5 in total

1.  Presentation and diagnosis of childhood-onset combined pituitary hormone deficiency: A single center experience from over 30 years.

Authors:  Johanna Hietamäki; Juho Kärkinen; Anna-Pauliina Iivonen; Kirsi Vaaralahti; Annika Tarkkanen; Henrikki Almusa; Hanna Huopio; Matti Hero; Päivi J Miettinen; Taneli Raivio
Journal:  EClinicalMedicine       Date:  2022-07-18

2.  Congenital hypopituitarism and multiple midline defects in a newborn with non-familial Cat Eye syndrome.

Authors:  Gregorio Serra; Clara Giambrone; Vincenzo Antona; Francesca Cardella; Maurizio Carta; Marcello Cimador; Giovanni Corsello; Mario Giuffrè; Vincenzo Insinga; Maria Cristina Maggio; Marco Pensabene; Ingrid Anne Mandy Schierz; Ettore Piro
Journal:  Ital J Pediatr       Date:  2022-09-08       Impact factor: 3.288

Review 3.  Delayed Diagnosis of Congenital Combined Pituitary Hormone Deficiency including Severe Growth Hormone Deficiency in Children with Persistent Neonatal Hypoglycemia-Case Reports and Review.

Authors:  Joanna Smyczyńska; Natalia Pawelak; Maciej Hilczer; Andrzej Lewiński
Journal:  Int J Mol Sci       Date:  2022-09-21       Impact factor: 6.208

4.  A serious and unusual presentation of congenital isolated ACTH deficiency due to TBX19 mutation, beyond the neonatal period.

Authors:  Inês Henriques Vieira; Nádia Mourinho Bala; Fabiana Ramos; Isabel Dinis; Rita Cardoso; Joana Serra Caetano; Dírcea Rodrigues; Isabel Paiva; Alice Mirante
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2022-09-01

Review 5.  Growth hormone deficiency and replacement in children.

Authors:  Margaret C S Boguszewski
Journal:  Rev Endocr Metab Disord       Date:  2020-10-08       Impact factor: 6.514

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.